- Home
- NSSC vs MNKD Comparison
NSSC vs MNKD Comparison
Compare NSSC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSSC | MNKD |
|---|---|---|
| Founded | 1969 | 1991 |
| Country | United States | United States |
| Employees | 1061 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1994 | 2004 |
Fundamental Metrics
Financial Performance| Metric | NSSC | MNKD |
|---|---|---|
| Price | $37.95 | $4.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $48.17 | $8.69 |
| AVG Volume (30 Days) | 464.1K | ★ 5.0M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | $181,621,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $13.63 | $35.81 |
| Revenue Next Year | $10.05 | $11.89 |
| P/E Ratio | $54.86 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $29.27 | $2.23 |
| 52 Week High | $47.61 | $6.51 |
Technical Indicators
Market Signals| Indicator | NSSC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 51.37 | 57.30 |
| Support Level | $37.43 | $3.77 |
| Resistance Level | $38.25 | $4.29 |
| Average True Range (ATR) | 1.16 | 0.23 |
| MACD | 0.23 | 0.00 |
| Stochastic Oscillator | 56.41 | 48.42 |
Price Performance
Historical ComparisonAbout NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.